NCT02123654: UNITY 3: A Japanese Phase 3 Study of a Daclatasvir/Asunaprevir/BMS-791325 in Subjects With Genotype 1 Chronic Hepatitis C |
|
|
| Completed | 3 | 297 | Japan | Daclatasvir, Asunaprevir, DCV 3DAA, Daclatasvir 30 mg /Asunaprevir 200 mg /BMS-791325 75 mg fixed dose combination, Placebo for DCV 3DAA, Placebo for Daclatasvir, Placebo for Asunaprevir | Bristol-Myers Squibb | Hepatitis C Virus Infection | 01/15 | 08/15 | | |